Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash from Operations (2020 - 2025)

Lyell Immunopharma's Cash from Operations history spans 6 years, with the latest figure at 28577000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 18.45% year-over-year to 28577000.0; the TTM value through Sep 2025 reached 165015000.0, down 5.92%, while the annual FY2024 figure was 162394000.0, 0.79% up from the prior year.
  • Cash from Operations for Q3 2025 was 28577000.0 at Lyell Immunopharma, up from 34458000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 25492000.0 in Q3 2021 and bottomed at 54738000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 38094000.0 (2024), against an average of 38929736.84.
  • The largest annual shift saw Cash from Operations crashed 45.55% in 2022 before it increased 18.45% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 33213000.0 in 2021, then dropped by 21.24% to 40267000.0 in 2022, then dropped by 0.91% to 40635000.0 in 2023, then fell by 16.26% to 47242000.0 in 2024, then surged by 39.51% to 28577000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Cash from Operations are 28577000.0 (Q3 2025), 34458000.0 (Q2 2025), and 54738000.0 (Q1 2025).